Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 2/20 | 0.36 |
| ▸ | F2 | P00734 | 3/20 | 0.34 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.34 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.34 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | SCN1A | P35498 | 2/20 | 0.33 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.33 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3534503 | 0.82 | HTR1B (0.40) | CA2CA1CA9HTR6F2 | |
| SCHEMBL3535404 | 0.82 | HTR1B (0.42) | CA2CA1CA9HTR6MEN1 | |
| SCHEMBL4843310 | 0.82 | CYP19A1 (0.36) | CA2CA1CA9HTR6ALDH1A1 | |
| SCHEMBL3531354 | 0.71 | CA1 (0.35) | CA2CA1CA9HTR6F2 | |
| SCHEMBL14006356 | 0.70 | HTR6 (0.36) | CA2CA1CA9HTR6MAOA | |
| SCHEMBL3531590 | 0.70 | HTR6 (0.39) | CA2CA1CA9HTR6F2 | |
| SCHEMBL5014728 | 0.68 | F2 (0.35) | CA2CA1CA9HTR6F2 | |
| SCHEMBL3534295 | 0.68 | HTR1B (0.40) | CA2CA1CA9HTR6F2 | |
| SCHEMBL4837518 | 0.68 | AKR1B1 (0.42) | HTR6 | |
| SCHEMBL3533897 | 0.68 | CYP19A1 (0.38) | HTR6CYP3A4CASP1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080280894-A1 | DIHYDRO[1,4]OXAZINO[2,3,4-hi]INDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2008-11-13 | — | — | US | disclosed |
| US-20080280894-A1 | DIHYDRO[1,4]OXAZINO[2,3,4-hi]INDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2008-11-13 | — | — | US | disclosed |
| US-20080280894-A1 | DIHYDRO[1,4]OXAZINO[2,3,4-hi]INDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2008-11-13 | — | — | US | disclosed |
| US-7429582-B2 | Dihydro[1,4]oxazino[2,3,4-hi]indazole derivatives as 5-hydroxytryptamine-6 ligands and use thereof in the treatment of attention deficit disorders | WYETH (US) | 2008-09-30 | — | — | US | disclosed |
| US-7429582-B2 | Dihydro[1,4]oxazino[2,3,4-hi]indazole derivatives as 5-hydroxytryptamine-6 ligands and use thereof in the treatment of attention deficit disorders | WYETH (US) | 2008-09-30 | — | — | US | disclosed |
| US-7429582-B2 | Dihydro[1,4]oxazino[2,3,4-hi]indazole derivatives as 5-hydroxytryptamine-6 ligands and use thereof in the treatment of attention deficit disorders | WYETH (US) | 2008-09-30 | — | — | US | disclosed |
| WO-2007120599-A2 | DIHYDRO[1,4]OXAZINO[2,3,4-HI]INDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2007-10-25 | — | — | WO | disclosed |
| WO-2007120599-A2 | DIHYDRO[1,4]OXAZINO[2,3,4-HI]INDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2007-10-25 | — | — | WO | disclosed |
| US-20070244105-A1 | Dihydro[1,4]oxazino[2,3,4-hi]indazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070244105-A1 | Dihydro[1,4]oxazino[2,3,4-hi]indazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070244105-A1 | Dihydro[1,4]oxazino[2,3,4-hi]indazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280894-A1 | DIHYDRO[1,4]OXAZINO[2,3,4-hi]INDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | HTR6, HTR5A, HTR2C | CA2 3098/4885CA1 3001/4885CA9 4533/4885 |
| US-20070244105-A1 | Dihydro[1,4]oxazino[2,3,4-hi]indazole derivatives as 5-hydroxytryptamine-6 ligands | HTR6, HTR5A, HTR2C | CA2 3098/4885CA1 3001/4885CA9 4533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.